Shanghai Yuguan Biotechnology

Shanghai Yuguan Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of novel small molecule drugs. The company focuses on high-selectivity inhibitors and targeted protein degradation (TPD) technologies, including PROTACs and molecular glues, to treat cancer and autoimmune disorders. Its lead program, YG-001, is a potent and selective JAK1 inhibitor currently in Phase 1/2 clinical trials for indications such as atopic dermatitis and rheumatoid arthritis. Yuguan utilizes a proprietary drug discovery platform that integrates structural biology and medicinal chemistry to target historically challenging proteins. The company aims to provide innovative and effective therapeutic solutions for patients worldwide through its robust internal R&D capabilities.